{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:31:27Z","timestamp":1775064687594,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020305","name":"ARCA biopharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jchf.2024.08.023","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T19:05:07Z","timestamp":1732129507000},"page":"573-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Symptoms Burden as a Clinical Outcomes Assessment in Heart\u00a0Failure Patients With Atrial Fibrillation"],"prefix":"10.1016","volume":"13","author":[{"given":"Ian A.","family":"Carroll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy S.","family":"Tzou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"DeMets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-4698","authenticated-orcid":false,"given":"Michael R.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.08.023_bib1","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart\u00a0failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.08.023_bib2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2VASc Score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.08.023_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.amjmed.2014.06.006","article-title":"New onset atrial fibrillation predicts heart failure progression","volume":"127","author":"Aleong","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2024.08.023_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/hrt.78.6.564","article-title":"Atrial fibrillation is associated with a lower exercise capacity in chronic heart failure patients","volume":"78","author":"Pardaens","year":"1997","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2024.08.023_bib5","first-page":"585","article-title":"Effect of atrial fibrillation on cognitive function in heart failure patients","volume":"18","author":"Ktenopoulos","year":"2021","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrcardio.2015.191","article-title":"Comorbidity of atrial fibrillation and heart failure","volume":"13","author":"Ling","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib7","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2024.08.023_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.08.023_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cardfail.2007.02.009","article-title":"The safety of amiodarone in patients with heart failure","volume":"13","author":"Torp-Pedersen","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.08.023_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.08.023_bib11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.08.023_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.880","article-title":"Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation-Insights from the German Ablation Registry","volume":"9","author":"Schleberger","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jchf.2024.08.023_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jchf.2012.10.001","article-title":"Treatment of the heart failure patient with atrial fibrillation: A major unmet need","volume":"1","author":"Bristow","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.08.023_bib15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jchf.2019.04.004","article-title":"Bucindolol for the maintenance of sinus rhythm in a genotype-defined HF population","volume":"7","author":"Piccini","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.08.023_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.08.023_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0002-9149(03)00974-3","article-title":"Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation","volume":"92","author":"Pritchett","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009591","article-title":"Bucindolol decreases atrial fibrillation burden in patients with heart Failure and the ADRB1 Arg389Arg genotype","volume":"14","author":"Piccini","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/europace\/eun384","article-title":"A\u00a0preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology","volume":"11","author":"Arya","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.jchf.2024.08.023_bib20","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A\u00a0polymorphism within a conserved \u03b21-adrenergic receptor motif alters cardiac function and \u03b2-blocker response in human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2024.08.023_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/CIRCEP.111.969618","article-title":"Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure","volume":"61","author":"Aleong","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jchf.2013.04.002","article-title":"Prevention of atrial fibrillation by bucindolol is dependent on the beta-1 389 Arg\/Gly adrenergic receptor polymorphism","volume":"1","author":"Aleong","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.08.023_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.hroo.2021.11.005","article-title":"Dose-limiting, adverse event-associated bradycardia with \u03b2-blocker treatment of atrial fibrillation in the GENETIC-AF trial","volume":"3","author":"Abraham","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.jchf.2024.08.023_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/CIRCEP.110.958033","article-title":"Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation","volume":"4","author":"Spertus","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jacep.2019.03.008","article-title":"Patient reported outcomes in atrial fibrillation research: results of a clinicaltrials.gov analysis","volume":"5","author":"Steinberg","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.hrthm.2005.01.028","article-title":"Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation","volume":"2","author":"Darbar","year":"2005","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jchf.2024.08.023_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42444-019-0009-9","article-title":"Characteristics of symptom burden in atrial fibrillation with concomitant heart failure","volume":"21","author":"Heo","year":"2020","journal-title":"Int J Arrhythm"},{"key":"10.1016\/j.jchf.2024.08.023_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jchf.2024.08.023_bib29","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurheartj\/ehu205","article-title":"The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials","volume":"35","author":"Anker","year":"2014","journal-title":"Eur Heart J"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924006784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924006784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:32:05Z","timestamp":1744518725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924006784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2213177924006784"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.08.023","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptoms Burden as a Clinical Outcomes Assessment in Heart\u00a0Failure Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}